Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Mol Cancer Ther. 2014 Oct 24;13(12):3074–3085. doi: 10.1158/1535-7163.MCT-13-1001

Figure 3. Changes in ADAM9 protease activities, invasion, and proliferation with treatment of RAV-18.

Figure 3

(A) When cells with high ADAM9 protease activity were treated with RAV-18, a dose-dependent decrease in protease activity was seen (from SNU-638 to MKN-28). However, cell lines with low ADAM9 protease activity showed no change in protease activities (from YCC-6 to Hs746T). (B) Cell lines with high ADAM9 activity treated with RAV-18 showed dose-dependent inhibition of proliferation. However, the proliferation of cell lines with low ADAM9 activity was not inhibited. (C) RAV-18 also dose-dependently reduced invasiveness in cell lines with high ADAM9 activity, but did not influence invasiveness of low activity cells (*; p < 0.05). (D) When cell lines were treated with RAV-18, pEGFR and pERK expression was dose-dependently decreased in cell lines expressing high ADAM9; low-expressing cell lines did not demonstrate a change.